832 results about "Cyclic compound" patented technology

Graphitic nanotubes, which includes tubular fullerenes (commonly called "buckytubes") and fibrils, which are functionalized by chemical substitution or by adsorption of functional moieties. More specifically the invention relates to graphitic nanotubes which are uniformly or non-uniformly substituted with chemical moieties or upon which certain cyclic compounds are adsorbed and to complex structures comprised of such functionalized fibrils linked to one another. The invention also relates to methods of introducing functional groups onto the surface of such fibrils.

A conductive composition comprises a π conjugated conductive polymer, a dopant, and a nitrogen-containing aromatic cyclic compound. A capacitor comprises an anode composed of a porous material of valve metal, a dielectric layer formed by oxidizing the surface of the anode, and a cathode provided on the dielectric layer and having a solid electrolyte layer containing a π conjugated conductive polymer, which comprises an electron donor compound containing an electron donor element provided between the dielectric layer and the cathode. Another capacitor is based on the above-described capacitor, wherein the solid electrolyte layer further comprises a dopant and a nitrogen-containing aromatic cyclic compound. An antistatic coating material comprises a π conjugated conductive polymer, a solubilizing polymer containing an anion group and/or an electron attractive group, a nitrogen-containing aromatic cyclic compound, and a solvent. An antistatic coating is formed by applying the antistatic coating material.

A flame-retardant resin composition comprises 10 to 300 parts by weight of a flame retardant (B) and 1 to 200 parts by weight of an inorganic filler (C) (a glass fiber and/or a glass flake), relative to 100 parts by weight of a base resin (A). The flame retardant (B) comprises a polyphenylene oxide-series resin and/or a polyphenylene sulfide-series resin (B1), a phosphoric ester (B2), and a nitrogen-containing cyclic compound (B3) (for example, a polyphosphate of an amino group-containing triazine compound). The inorganic filler (C) has been treated with a surface-treatment agent or sizing agent containing a novolak epoxy resin. Such a resin composition is useful for obtaining a shaped article which has been inhibited from dripping and to which flame retardancy is highly imparted.

An alignment film includes a first pre-tilt functional group, a second pre-tilt functional group and a first vertical alignment functional group, which are linked to polysiloxane on a substrate. The first vertical alignment functional group includes a cyclic compound and is aligned substantially perpendicularly to the substrate. The first pre-tilt functional group is cross-linked to the second pre-tilt functional group and tilted with respect to the substrate.

The present provides cyclic compounds capable of modulating IgE production, as well as IL-4 induced processes associated therewith, and methods of using the cyclic compounds in a variety of in vitro and in vitro contexts.

Proteolytically stable small molecule β-turn peptidomimetic compounds have been identified as agonists or antagonists of neurotrophin receptors, such as TrkA. A compound of particular interest binds the immunoglobulin-like C2 region of the extracellular domain of TrkA, competes the binding of another TrkA ligand, affords selective trophic protection to TrkA-expressing cell lines and neuronal primary cultures, and induces the differentiation of primary neuronal cultures. The small β-turn peptidomimetic compounds of the invention can activate a tyrosine kinase neurotrophin receptor that normally binds a relatively large protein ligand. Such compounds that bind the extracellular domain of Trk receptors are useful pharmacological agents to address disorders where Trk receptors play a role, by targeting populations selectively.

Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: X<1>-Y<1>-Z<1> (I) wherein X<1 >is optionally substituted aryl, optionally substituted heteroaryl or the like; Y<1 >is -NRCO-(CH2)0-2- or the like (wherein Ris hydrogen atom or the like); and Z<1 >is a cyclic group fused the same or different two ring selected from optionally substituted carbocyclic group and optionally substituted heterocyclic group.

A lithium secondary battery includes: an electrode body having a positive electrode, a negative electrode, and a separator, the positive electrode and the negative electrode being wound or laminated by means of the separator; and a nonaqueous electrolyte solution containing a lithium compound as a electrolyte. At least one of the positive electrode, the negative electrode, the separator, the nonaqueous electrolyte solution contains at least one of: (a) an organic and/or inorganic inhibitor, which functions as a Cu-corrosion inhibitor or a Cu-trapping agent, (b) a compound having an organic base and an inorganic acid which are unitarily combined in a molecule, (c) a cyclic compound containing a N-O radical in a molecular structure, (d) a cyclic compound which becomes a Mn<2+> supplier in the nonaqueous electrolyte solution, (e) a compound containing an atom showing Lewis acidity and an atom showing Lewis basisity in one molecule, (f) a three-dimensional siloxane compound, and (g) a nonionic surfactant; or the nonaqueous electrolyte solution contains: (h) a water-extracting agent, or (i) a hydrofluoric acid-extracting agent. This lithium secondary battery exhibits an excellent effect that self-discharge property, cycle characteristics, long period stability and reliability can be planned.

The present invention recites a method comprising reacting in a solvent in the presence of a basea) at least one diacidic monomer comprising about 1 to 100 mole % of at least one light-absorbing monomer having a light absorption maximum between about 300 nm and about 1200 nm and 99-0 mole % of a non-light absorbing monomer which does not absorb significant light at wavelengths above 300 nm or has a light absorption maximum below 300 nm, withb) an organic compound of Formula IIwherein B is a divalent organic radical to form a light absorbing composition comprising a mixture of a polymer having the formulaand a cyclic compound having the general formulawherein B is as defined above; n is at least 2, m is 1, 2, 3 or 4 and A comprises the residue of a diacidic monomer comprising about 1 to 100 mole % of at least one light-absorbing monomer having a light absorption maximum between about 300 nm and about 1000 nm and wherein the remaining portion of A comprises the residue of a non-light absorbing monomer which does not absorb significant light at wavelengths above 300 nm or has a light absorption maximum below 300 nm.

The present invention relates to injecting a cycline compound into a diseased intervertebral disc.

A flame-retardant resin composition comprises (A) abase resin; (B) a flame retardant comprising (B1) at least one aromatic resin selected from a pblyphenylene oxide-series resin and a polyphenylene sulfide-series resin, (B2) a phosphoric ester, and (B3) a nitrogen-containing cyclic compound; and (C) a styrenic resin having a melt flow rate of not more than 8 g/10 minutes. The base resin may be a polyester-series resin. The styrenic resin (C) may be a styrenic resin having a melt flow rate of 0.1 g/10 minutes to not more than 5 g/10 minutes. The phosphoric ester (B2) may be a condensed phosphoric ester, and the nitrogen-containing cyclic compound (B3) may be a polyphosphate of an amino group-containing triazine compound, a polyphosphoric acid amide, or others. The present invention provides a flame-retardant resin composition which has been flame-retarded without using a halogen-containing flame retardant.

A photoalignment material includes an alignment polymer, a photoalignment additive including a compound represented by the following Chemical Formula 1 and an organic solvent.

In Chemical Formula 1, R₁ represents a cyclic compound. A and B independently represent a single bond or —(C_nH_2n)—. “n” represents an integer in a range of 1 to 12. Each —CH₂— of A and/or B may be replaced with

R₃ represents an alkyl group having 1 to 12 carbon atoms, and each —CH₂— of A and/or B may be replaced with —O—. R₄ represents

In Chemical Formula 1, each hydrogen atom excluding hydrogen atoms of R₄ may be replaced with chlorine (Cl) or fluorine (F).

Thus, an alignment layer having an orientation may be formed without an alignment polymer having a photoreactive portion, and the density of the alignment layer may be increased.

This invention is directed to a method of treating depression in a subject, comprising the step of administering a therapeutically effective amount of a conventional antidepressant and, in addition, administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member Rx selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R₁ and R₂ can be the same or different each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R₁ and R₂ can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.

The present invention provides novel C-linked cyclic compounds and analogues of Formula (I):

or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y₁ receptor which can be used as medicaments.

The present invention provides a novel compound having an excellent PPAR agonist action. More specifically, it provides a compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them.

Wherein a, b and c are the same as or different from one another and each represents 0 to 4; R¹ to R⁶ are the same as or different from one another and each represents a hydrogen atom, a hydroxyl group, a cyano group, a halogen atom, etc.;

• A¹ and A² are the same as or different from each other and each represents a single bond, an oxygen atom, etc.; L, M and T each represent a single bond, an alkylene group having one to six carbon atoms, etc.; W represents a carboxyl group;

the partial structure represented by the formula:  represents a single bond or a double bond;

X represents a single bond, an oxygen atom, —NR^X1CQ¹O—, etc.;

Y represents Y¹—Y²— (wherein Y¹ represents a 5 to 14-membered aromatic ring having one to four substituents, etc.; and Y² represents a single bond or a 5 to 14-membered aromatic ring); and the ring Z represents a 5 to 14-membered aromatic ring which have one to four substituents selected form the above-mentioned Group A, may have one or more hetero atoms and may be partially saturated.

An ink jet ink composition comprising from about 30 to about 90% by weight of water, from about 0.5 to about 30% by weight of a composite colorant, from about 0.1 to about 10% by weight of natural or synthetic smectite clay mineral, and from about 10 to about 50% by weight of a humectant comprising a polyhydric alcohol or a nitrogen-containing cyclic compound.

The invention concerns compounds of formula (I): R-A-R' wherein: A is as defined in the description; R represents a group (V), (VI), (VII) or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R' represents a -(CH2)t-R5 group wherein t and R5 are as defined in the description